Brian Mendelsohn

Executive Director, ADCs Exelixis, Inc.

Seminars

Tuesday 4th November 2025
Presentation Sneak Peek:

Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC

  • XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
  • Laying out demonstration of in vitro bystander and ICD activity
  • Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
Tuesday 4th November 2025
Presentation Sneak Peek:

Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC

  • XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
  • Laying out demonstration of in vitro bystander and ICD activity
  • Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
Brian Mendelson - 16th World ADC San Diego